DME Capital Management LP Reduces Stock Position in LivaNova PLC (NASDAQ:LIVN)

DME Capital Management LP trimmed its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 51.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 644,269 shares of the company's stock after selling 688,535 shares during the quarter. LivaNova comprises about 1.7% of DME Capital Management LP's holdings, making the stock its 17th biggest position. DME Capital Management LP owned 1.19% of LivaNova worth $35,319,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LIVN. BNP Paribas Financial Markets increased its holdings in shares of LivaNova by 98.3% during the fourth quarter. BNP Paribas Financial Markets now owns 22,338 shares of the company's stock valued at $1,156,000 after acquiring an additional 11,075 shares in the last quarter. Norges Bank bought a new stake in LivaNova during the 4th quarter valued at $26,064,000. Trexquant Investment LP acquired a new position in LivaNova during the fourth quarter worth $1,079,000. Hsbc Holdings PLC lifted its stake in shares of LivaNova by 137.9% in the fourth quarter. Hsbc Holdings PLC now owns 21,206 shares of the company's stock valued at $1,107,000 after buying an additional 12,291 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of LivaNova during the fourth quarter valued at about $2,090,000. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Baird R W raised LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. Robert W. Baird raised LivaNova from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $55.00 to $66.00 in a research report on Tuesday, September 17th. Finally, Needham & Company LLC upped their price target on LivaNova from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $70.80.

LivaNova Stock Performance

Shares of LIVN stock traded up $0.59 during trading on Thursday, hitting $52.31. The company's stock had a trading volume of 341,754 shares, compared to its average volume of 648,943. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. The company has a market cap of $2.84 billion, a PE ratio of -86.87 and a beta of 1.00. The business has a fifty day moving average of $48.73 and a 200-day moving average of $53.33. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.66 by $0.15. The firm had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. As a group, research analysts anticipate that LivaNova PLC will post 2.58 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.